EMA Authorised: Bavencio (avelumab) — Merck Europe B.V.

View source ↗

Summary

The European Medicines Agency authorised a new indication for Bavencio (avelumab) for neuroendocrine tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• BAVENCIO (AVELUMAB)

Snippet

Status: Authorised. Therapeutic area: Neuroendocrine Tumors. MAH: Merck Europe B.V.. Decision date: 27/11/2025